TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04054414
Drug: PMZ-1620 along with standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMZ-1620 (sovateltide) is an endothelin-B receptor agonist. PMZ-1620 has the potential to be a first-in-class neuronal progenitor cell therapeutics that is likely to promote quicker recovery and improve neurological outcome in cerebral ischemic stroke patients.
Study: NCT00673127
Drug: Ketoconazole, Hydrocortisone and Dutasteride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole: 200mg orally three times a day on an empty stomach. Hydrocortisone: 30mg in the morning and 10mg in the evening. Pills should be taken with food or milk.~Dutasteride: 0.5mg orally once a day on an empty stomach or after eating a meal
Study: NCT00119262
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02312011
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00119262
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00119262
Drug: aromatase inhibition therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive aromatase inhibition therapy
Study: NCT01338376
Drug: Scilin®M30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be treated with Scilin®M30 twice daily
Study: NCT02480803
Drug: Continuous intrajejunal infusion of levodopa-carbidopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous delivery of levodopa-carbidopa intestinal gel through an intrajejunal percutaneous tube (Duodopa, CLI, CILI)
Study: NCT00001626
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide
Study: NCT04567810
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching anti-SARS-CoV-2 IgY preparation in liquid administered with a bottle with a dropper.
Study: NCT01458847
Drug: cis-UCA solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort I: 2% cis-UCA solution (50 ml); min 3, max 12 patients
Study: NCT01458847
Drug: cis-UCA solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort II: 4% cis-UCA solution (50 ml); min 0, max 12 patients
Study: NCT01458847
Drug: cis-UCA solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort III: 6% cis-UCA solution (50 ml); min 0, max 12 patients
Study: NCT02164097
Drug: ODSH
Normalized name: Octasulfated Disaccharide Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03401047
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive graded doses of transdermal estradiol patches for up to 7 days. Blood estradiol tests will be performed daily, and the number of estradiol patches used will be adjusted to maintain serum estradiol levels of 250-400 pg/ml. Estradiol is a natural hormone.
Study: NCT02744339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo sham-titrated TID
Study: NCT00985270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03051893
Drug: Chronocort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified formulation of hydrocortisone
Study: NCT02781311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, orally, BID for 24 weeks.
Study: NCT01813305
Drug: CSTC1 Matched vehicle
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05006222
Drug: Enzyme Replacement Agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy is one such treatment and used for the management of some subtypes of MPS disease. Enzyme replacement therapy (ERT) is based on the concept of replacing the missing enzyme in the circulation to prevent the build-up of glycosaminoglycan (GAG) in the tissues
Study: NCT01999777
Drug: USL261
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01999777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01098526
Drug: GSK1349572
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1349572 is an experimental drug under development for the treatment of HIV. It is in the class of integrase inhibitors.
Study: NCT04639986
Drug: Capecitabine Oral Product
Normalized name: capecitabine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine is administered orally (PO) following recommended doses and regimens as per approved package inserts.
Study: NCT00814645
Drug: Placebo and AIR001 Inhalation Solution (Expansion arm)
Approvals — FDA: no, EMA: no, PMDA: no
Description: On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.
Study: NCT00338260
Drug: MK0954, /Duration of Treatment : 5 Years
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005675
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI placebo daily for 15 months
Study: NCT01155791
Drug: Biosyn
Normalized name: biosynthetic glove
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dosage varies
Study: NCT04542408
Drug: Anticoagulation Agents (Edoxaban and/or high dose LMWH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-hospital (ICU \& normal ward): weight-adapted LMWH, high dose/ therapeutic dose (according to respective SmPC) After discharge and in ambulatory patients: Edoxaban according to SmPC until
Study: NCT04542408
Drug: Low dose Low molecular weight heparin or Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-hospital (ICU \& normal ward): LMWH, prophylactic dose as part of SOC After discharge and in ambulatory patients: Administration of oral pla-cebo according to the dosing rules for Edoxaban
Study: NCT02729935
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An equal volume of saline
Study: NCT02039661
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03588598
Drug: SHC014748M
Approvals — FDA: no, EMA: no, PMDA: no
Description: a selective PI3Kδ inhibitor
Study: NCT00914290
Drug: IPX056
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPX056 ER capsule containing 10 mg baclofen
Study: NCT01028079
Drug: Acetylsalicylic Acid (Aspirin, BAYE4465)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 1000 mg (solid dose caplet) to be given three times daily as for 2 consecutive days (48 hours), followed by Aspirin 1000 mg (solid dose caplet) to be taken as per need, but not more than three times daily for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 3000 mg Aspirin.
Study: NCT00428025
Drug: diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg diclofenac rectal suppository
Study: NCT00428025
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: similar shape and size suppository
Study: NCT00801411
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00801411
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01028079
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 400 mg caplet to be given three times a day as for 2 consecutive days (48 hours), followed by ibuprofen 400 mg caplet to be given as per need, but not more than three times a day for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 1200 mg ibuprofen.
Study: NCT01028079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two placebos: Placebo Aspirin and Placebo Ibuprofen) to be given three times a day for a maximum of 5 consecutive days in the same regimen as for Experimental Drug and Active Comparator.
Study: NCT02146222
Drug: VEGFR/PDGFR dual kinase inhibitor X-82
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04292314
Drug: Nigella Sativa Oil
Normalized name: Nigella sativa seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nigella sativa supplementation (1g black seed oil contain 1% thymoquinone) per day for 8 consecutive months up to 10 months
Study: NCT01227928
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 800 mg daily for 24 months
Study: NCT01084993
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 70 U/kg
Study: NCT01267981
Drug: Standard diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: After the lunch the day before the exploration, drink only clear liquids and stop solid food.~From 10 pm, stay fasting, don't drink except the usual drugs taken with mouthful of water until the exploration by video-capsule endoscopy.
Study: NCT03192969
Drug: Glucocorticoid Treatment
Normalized name: Glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid taper (up to 52-week or 28-week of oral prednisone/prednisolone)
Study: NCT01190722
Drug: etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg once daily for the 1st 6 postoperative days
Study: NCT01190722
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg oral 3 times daily the 1st 6 postoperative days
Study: NCT00338988
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1500 mg/m\^2 PO twice daily x 14 days.
Study: NCT03616795
Drug: LY3154207
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03616795
Drug: [14C]-LY3154207
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03293069
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: the placebo twice daily morning and evening.
Study: NCT02680119
Drug: Nexium 40 mg DR Capsules of AstraZeneca LP, USA.
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, crossover
Study: NCT00405704
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cherry flavored liquid suspension matched to active comparator.
Study: NCT04134884
Drug: ASTX727
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASTX727 will be taken on days 1 and 3, days 1,3,5 or days 1 through 5 of the 28 day cycle at doses of 10 mg:100 mg or 15 mg:100 mg depending on cohort assignment
Study: NCT04529811
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02194829
Drug: AZD1775
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT02325583
Drug: 30% Glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORAL 30% GLUCOSE 0,5-2 ML
Study: NCT00600847
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose for 7 days, oral
Study: NCT04071171
Drug: CVVH with Phoxilium® in the first 48h after randomization
Approvals — FDA: no, EMA: no, PMDA: no
Description: After randomization into the Phoxilium®-group, CVVH will be initiated with Phoxilium® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
Study: NCT01741389
Drug: Melatonin (Circadin)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00636480
Drug: ChloraPrep One Step
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer topically
Study: NCT00636480
Drug: Sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl solution
Study: NCT04415645
Drug: [14C]-VVZ-149
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single IV infusion of radio-labeled VVZ-149
Study: NCT00561717
Drug: Placebo and Placebo (spray and Tablet)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
Study: NCT01921907
Drug: AD17137 topical treatment
Normalized name: Acne Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01921907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04071171
Drug: CVVH with Biphozyl® in the first 48h after randomization
Approvals — FDA: no, EMA: no, PMDA: no
Description: After randomization into the Biphozyl®-group, CVVH will be initiated with Biphozyl® as a replacement fluid and maintained for 48h, respectively until the crossover. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
Study: NCT01010204
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomly assigned to receive either varenicline or placebo for 12 weeks. Patients assigned to varenicline will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study, i.e. 11 weeks. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline. Patients will be instructed to take study medication after meals with a glass of water.
Study: NCT03204500
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally under the same conditions
Study: NCT03186586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo one pill a day for 5 days at the bleeding episode
Study: NCT03598699
Drug: AXR-159
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXR-159 Ophthalmic Solution
Study: NCT03598699
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXR-159 Ophthalmic Solution Vehicle
Study: NCT04486313
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo tablets administered orally twice daily with food for 5 days
Study: NCT04071171
Drug: CVVH with Phoxilium® in the second 48h after randomization (after previous 48h with Biphozyl®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48h post randomization, respectively after the cross-over CVVH will be continued with Phoxilium® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
Study: NCT04071171
Drug: CVVH with Biphozyl® in the second 48h after randomization (after previous 48h with Phoxilium®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48h post randomization, respectively after the cross-over CVVH will be continued with Biphozyl® for another 48h. Anticoagulation is delivered as pre-filter RCA with Regiocit® (Gambro Lundia AB, Sweden). For antagonisation of Regiocit®, a calcium solution (calcium chloride, with or without magnesium chloride) will be used post-filter.
Study: NCT02609152
Drug: Continuous perfusion of saline
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the control arm of the study, a continuous infusion of normal saline will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. A H4, the doctor in charge is free to gradually continue or stop the infusion.
Study: NCT01159483
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT00037115
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03752242
Drug: BMX-010 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and efficacy of BMX-010 in topical treatment of acne.
Study: NCT00307164
Drug: NucleomaxX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 g sachet taken orally three times daily
Study: NCT00307164
Drug: NucleomaxX placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 g placebo sachet taken orally three times daily
Study: NCT02020746
Drug: EscharEx
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02543099
Drug: policosanol
Normalized name: POLICOSANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive policosanol 20mg Qd
Study: NCT02543099
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo 20mg Qd;
Study: NCT01496365
Drug: DS-5565 tablet
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg and 10mg tablets
Study: NCT01496365
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01496365
Drug: placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03017547
Drug: IC14
Normalized name: CATH,INTERMIT 14FR RELIAMED #PIC1416
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blocks CD14 signalling which is responsible for disease pathogenesis in ARDS
Study: NCT00469456
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral administration twice daily for 12 weeks
Study: NCT03732781
Drug: Radspherin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radspherin® suspension consists of degradable calcium carbonate microparticles with the α-emitting radionuclide 224Ra in suspension.~Radspherin® will be provided in a R10 vial filled with 10 mL suspension of 224Ra adsorbed on 1 g calcium carbonate microparticles. The volume to be administered will contain 0.7-1 g calcium carbonate microparticles with 1-7 MBq 224Ra. 224Ra has a half-life of 3.6 days.
Study: NCT00135577
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00408798
Drug: Intracutaneous injections of Botulinum Toxin A (Botox), 0.1 cc per injection site, which equals 10 units
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Detailed Description.
Study: NCT00855049
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal acetaminophen administration
Study: NCT02578914
Drug: NS2 Ophthalmic Drops Vehicle (0.0%)
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00855049
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen administration
Study: NCT00813098
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo dosing with daily oral intake
Study: NCT00766402
Drug: Tramadol /acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a combination tablet of 37.5 milligram (mg) tramadol and 325 mg acetaminophen, orally twice daily up to 8 weeks.
Study: NCT00766402
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive 50 mg diclofenac tablet, orally twice daily up to 8 weeks.
Study: NCT03626831
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of placebo
Study: NCT02367105
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily testosterone gel applied once daily in the morning to intact skin
Study: NCT02367105
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel for testosterone
Study: NCT02560389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill packaged to resemble levodopa
Study: NCT02560389
Drug: Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.
Study: NCT01377168
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02547441
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Gel
Study: NCT02025855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00024128
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02949232
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prednisolone will be will be initiated during the first week at 40mg/day for 3 days and 30mg/day for 4 days, followed by a decrease of 5mg/day per week during the remaining 5 weeks; in the second week, patients will use 25 mg/day, in the third week 20 mg/day is used etc. In the last week the patients will only take prednisolone on day 1-3 and day 5 and 7; a tapering scheme in line with the treatment guidelines for Inflammatory Bowel Diseases (2008).
Study: NCT02949232
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosing following the tapering scheme of the treatment of the treatment arm
Study: NCT02987998
Drug: Radiation
Normalized name: Miaderm Radiation Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation (1.8Gy/D to 45Gy in 25 fractions)
Study: NCT03317028
Drug: CS02 tablet and placebo tablet
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.
Study: NCT02500914
Drug: SC-002
Normalized name: heparinoids 0.002 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC-002 will be administered by IV infusion over approximately 30 minutes every 3 weeks
Study: NCT02980705
Drug: SUNPG1622 I dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection
Study: NCT02980705
Drug: Placebo dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection
Study: NCT01302938
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo of Tolterodine ER 4 mg will be taken with water every day with or without food. It should be swallowed whole without chewing.